Microsatellite instability in colorectal cancer

Asia-Pacific Journal of Clinical Oncology

Volumn 6, Issue 4, 2010, Pages 260-269

  Iacopetta, Barry ^a   Grieu, Fabienne ^b   Amanuel, Benhur ^b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b Anatomical Pathology   (Australia)

Author keywords

5 FU; Chemotherapy; Colorectal cancer; Lynch syndrome; Microsatellite instability; Mismatch repair

Indexed keywords

FLUOROURACIL; IRINOTECAN; OXALIPLATIN; PROTEIN BAX; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2;

CANCER SCREENING; CHROMOSOMAL INSTABILITY; CLINICAL TRIAL; DNA METHYLATION; DRUG TARGETING; GENE MUTATION; GERIATRIC PATIENT; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HETEROZYGOSITY; HISTOPATHOLOGY; HUMAN; LYMPHOCYTIC INFILTRATION; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; NUCLEOTIDE REPEAT; PHENOTYPE; POPULATION RESEARCH; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; REVIEW;

COLORECTAL NEOPLASMS; HUMANS; MICROSATELLITE INSTABILITY;

EID: 78649766938     PISSN: 17437555     EISSN: 17437563     Source Type: Journal    
DOI: 10.1111/j.1743-7563.2010.01335.x     Document Type: Review

References (86)

1. Ionov Y, Peinado M, Malkhosyan S, Shibata D, Perucho M. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 1993; 363: 558-61.
2. Thibodeau SN, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon. Science 1993; 260: 816-19.
3. Aaltonen LA, Peltomäki P, Leach FS et al. Clues to the pathogenesis of familial colorectal cancer. Science 1993; 260: 812-16.
4. Parsons R, Li GM, Longley M et al. Hypermutability and mismatch repair deficiency in RER+ tumor cells. Cell 1993; 75: 1227-36.
5. Hemminki A, Peltomäki P, Mecklin JP et al. Loss of the wild type MLH1 gene is a feature of hereditary nonpolyposis colorectal cancer. Nat Genet 1994; 8: 405-10.
6. Kane MF, Loda M, Gaida GM et al. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res 1997; 57: 808-11.
7. Markowitz S, Wang J, Myeroff L et al. Inactivation of the type II TGF-II receptor in colon cancer cells with microsatellite instability. Science 1995; 268: 1336-38.
8. Duval A, Hamelin R. Mutations at coding repeat sequences in mismatch repair deficient human cancers: toward a new concept of target genes for instability. Cancer Res 2002; 62: 2447-54.
9. Park J, Betel D, Gryfe R et al. Mutation profiling of mismatch repair-deficient colorectal cancers using an in silico genome scan to identify coding microsatellites. Cancer Res 2002; 62: 1284-8.
10. Hugo H, Cures A, Suraweera N et al. Mutations in the MYB intron I regulatory sequence increase transcription in colon cancers. Genes Chromosomes Cancer 2006; 45: 1143-54.
11. Giannini G, Rinaldi C, Ristori E et al. Mutations of an intronic repeat induce impaired MRE11 expression in primary human cancer with microsatellite instability. Oncogene 2004; 23: 2640-7.
12. Boland CR, Thibodeau SN, Hamilton SR et al. A National Cancer Institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998; 58: 5248-57.
13. Bacher JW, Flanagan LA, Smalley RL et al. Development of a fluorescent multiplex assay for detection of MSI-high tumors. Dis Markers 2004; 20: 237-50.
14. Murphy KM, Zhang S, Geiger T et al. Comparison of the microsatellite instability analysis system and the Bethesda panel for the determination of microsatellite instability in colorectal cancers. J Mol Diagn 2006; 8: 305-11.
15. Tomlinson I, Halford S, Aaltonen L, Hawkins N, Ward R. Does MSI-low exist? J Pathol 2002; 197: 6-13.
16. Perucho M, Correspondence RE, Boland CR et al. A National Cancer Institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1999; 59: 249-56.
17. Zhou XP, Hoang JM, Li YJ et al. Determination of the replication error phenotype in human tumors without the requirement for matching normal DNA by analysis of mononucleotide repeat microsatellites. Genes Chromosomes Cancer 1998; 21: 101-7.
18. Hoang JM, Cottu PH, Thuille B, Salmon RJ, Thomas G, Hamelin R. BAT-26, an indicator of the replication error phenotype in colorectal cancers and cell lines. Cancer Res 1997; 57: 300-3.
19. Pyatt R, Chadwick RB, Johnson CK, Adebamowo C, De La Chapelle A, Prior TW. Polymorphic variation at the BAT-25 and BAT-26 loci in individuals of African origin. Implications for microsatellite instability testing. Am J Pathol 1999; 155: 349-53.
20. Pastrello C, Baglioni S, Tibiletti MG et al. Stability of BAT26 in tumours of hereditary nonpolyposis colorectal cancer patients with MSH2 intragenic deletion. Eur J Hum Genet 2006; 14: 63-8.
21. Suraweera N, Duval A, Reperant M et al. Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCR. Gastroenterology 2002; 123: 1804-11.
22. Xicola RM, Llor X, Pons E et al. Performance of different microsatellite marker panels for detection of mismatch repair-deficient colorectal tumors. J Natl Cancer Inst 2007; 7: 244-52.
23. Samowitz WS, Curtin K, Ma KN et al. Microsatellite instability in sporadic colon cancer is associated with an improved prognosis at the population level. Cancer Epidemiol Biomarkers Prev 2001; 10: 917-23.
24. Ward RL, Turner J, Williams R et al. Routine testing for mismatch repair deficiency in sporadic colorectal cancer is justified. J Pathol 2005; 207: 377-84.
25. Malesci A, Laghi L, Bianchi P et al. Reduced likelihood of metastases in patients with microsatellite-unstable colorectal cancer. Clin Cancer Res 2007; 13: 3831-9.
26. Malkhosyan SR, Yamamoto H, Piao Z, Perucho M. Late onset and high incidence of colon cancer of the mutator phenotype with hypermethylated hMLH1 gene in women. Gastroenterology 2000; 119: 598.
27. Jass JR. HNPCC and sporadic MSI-H colorectal cancer: a review of the morphological similarities and differences. Fam Cancer 2004; 3: 93-100.
28. Clark AJ, Barnetson R, Farrington SM, Dunlop MG. Prognosis in DNA mismatch repair deficient colorectal cancer: are all MSI tumours equivalent? Fam Cancer 2004; 3: 85-91.
29. Ahuja N, Mohan AL, Li Q et al. Association between CpG island methylation and microsatellite instability in colorectal cancer. Cancer Res 1997; 57: 3370-4.
30. Iacopetta B, Watanabe T. Predictive value of microsatellite instability for benefit from adjuvant fluorouracil chemotherapy in colorectal cancer. Gut 2006; 55: 1671-2.
31. Poynter JN, Siegmund KD, Weisenberger DJ et al. Molecular characterization of MSI-H colorectal cancer by MLHI promoter methylation, immunohistochemistry, and mismatch repair germline mutation screening. Cancer Epidemiol Biomarkers Prev 2008; 17: 3208-15.
32. Chai SM, Zeps N, Shearwood AM et al. Screening for defective DNA mismatch repair in stage II and III colorectal cancer patients. Clin Gastroenterol Hepatol 2004; 2: 1017-25.
33. Wang C, Van Rijnsoever M, Grieu F et al. Prognostic significance of microsatellite instability and Ki-ras mutation type in stage II colorectal cancer. Oncology 2003; 64: 259-65.
34. Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 2005; 23: 609-18.
35. Morris M, Platell C, De Boer B, McCaul K, Iacopetta B. Population-based study of prognostic factors in stage II colonic cancer. Br J Surg 2006; 93: 866-71.
36. Morris EJ, Maughan NJ, Forman D, Quirke P. Who to treat with adjuvant therapy in Dukes B/stage II colorectal cancer? The need for high quality pathology. Gut 2007; 56: 1419-25.
37. Salama P, Phillips M, Grieu F et al. Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol 2009; 27: 186-92.
38. Frey DM, Droeser RA, Viehl CT et al. High frequency of tumor-infiltrating FOXP3(+) regulatory T cells predicts improved survival in mismatch repair-proficient colorectal cancer patients. Int J Cancer 2010; 126: 2635-43.
39. Aebi S, Fink D, Gordon R et al. Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells. Clin Cancer Res 1997; 3: 1763-7.
40. Meyers M, Wagner MW, Hwang HS, Kinsella TJ, Boothman DA. Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses. Cancer Res 2001; 61: 5193-201.
41. Elsaleh H, Joseph D, Grieu F, Zeps N, Spry N, Iacopetta B. Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet 2000; 355: 1745-50.
42. Ribic CM, Sargent DJ, Moore MJ et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003; 349: 247-57.
43. Des Guetz G, Schischmanoff O, Nicolas P, Perret GY, Morere JF, Uzzan B. Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis. Eur J Cancer 2009; 45: 1890-6.
44. Kim GP, Colangelo LH, Wieand HS et al. Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study. J Clin Oncol 2007; 25: 767-72.
45. Jover R, Zapater P, Castells A et al. Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer. Gut 2006; 55: 848-55.
46. Storojeva I, Boulay JL, Heinimann K et al. Prognostic and predictive relevance of microsatellite instability in colorectal cancer. Oncol Rep 2005; 14: 241-9.
47. Carethers JM, Smith EJ, Behling CA et al. Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer. Gastroenterology 2004; 126: 394-401.
48. Boland CR. Clinical uses of microsatellite instability testing in colorectal cancer: an ongoing challenge. J Clin Oncol 2007; 25: 754-6.
49. Sinicrope FA, Sargent DJ. Clinical implications of microsatellite instability in sporadic colon cancers. Curr Opin Oncol 2009; 21: 369-73.
50. Van Rijnsoever M, Elsaleh H, Joseph D, McCaul K, Iacopetta B. CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer. Clin Cancer Res 2003; 9: 2898-903.
51. Sargent D, Marsoni S, Monges G et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 2010; 28: 3219-26.
52. Ng K, Schrag D. Microsatellite instability and adjuvant fluorouracil chemotherapy: a mismatch? J Clin Oncol 2010; 28: 3207-10.
53. Fink D, Nebel S, Aebi S et al. The role of DNA mismatch repair in platinum drug resistance. Cancer Res 1996; 56: 4881-6.
54. Fink D, Zheng H, Nebel S et al. In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. Cancer Res 1997; 57: 1841-5.
55. Müller CI, Schulmann K, Reinacher-Schick A et al. Predictive and prognostic value of microsatellite instability in patients with advanced colorectal cancer treated with a fluoropyrimidine and oxaliplatin containing first-line chemotherapy. A report of the AIO Colorectal Study Group. Int J Colorectal Dis 2008; 23: 1033-9.
56. Jacob S, Aguado M, Fallik D, Praz F. The role of the DNA mismatch repair system in the cytotoxicity of the topoisomerase inhibitors camptothecin and etoposide to human colorectal cancer cells. Cancer Res 2001; 61: 6555-62.
57. Fallik D, Borrini F, Boige V et al. Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancer. Cancer Res 2003; 63: 5738-44.
58. Vilar E, Scaltriti M, Balmaña J et al. Microsatellite instability due to hMLH1 deficiency is associated with increased cytotoxicity to irinotecan in human colorectal cancer cell lines. Br J Cancer 2008; 99: 1607-12.
59. Bras-Gonçalves RA, Rosty C, Laurent-Puig P, Soulié P, Dutrillaux B, Poupon MF. Sensitivity to CPT-11 of xenografted human colorectal cancers as a function of microsatellite instability and p53 status. Br J Cancer 2000; 82: 913-23.
60. Bertagnolli MM, Niedzwiecki D, Compton CC et al. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: cancer and Leukemia Group B Protocol 89803. J Clin Oncol 2009; 27: 1814-21.
61. Vilar E, Mukherjee B, Kuick R et al. Gene expression patterns in mismatch repair-deficient colorectal cancers highlight the potential therapeutic role of inhibitors of the phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin pathway. Clin Cancer Res 2009; 15: 2829-39.
62. Vilar E, Gruber SB. Microsatellite instability in colorectal cancer - the stable evidence. Nat Rev Clin Oncol 2010; 7: 153-62.
63. Kaelin WG Jr. The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 2005; 5: 689-98.
64. Fong PC, Boss DS, Yap TA et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361: 123-34.
65. Vilar E, Chow A, Raskin L et al. Preclinical testing of the PARP inhibitor ABT-888 in microsatellite instable colorectal cancer. J Clin Oncol 2009; 27: 11028 (abstract).
66. Martin SA, McCarthy A, Barber LJ et al. Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair gene MSH2. EMBO Mol Med 2009; 1: 323-37.
67. Swanton C, Caldas C. Molecular classification of solid tumours: towards pathway-driven therapeutics. Br J Cancer 2009; 100: 1517-22.
68. Aaltonen LA, Salovaara R, Kristo P et al. Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med 1998; 338: 1481-7.
69. Salovaara R, Loukola A, Kristo P et al. Population-based molecular detection of hereditary nonpolyposis colorectal cancer. J Clin Oncol 2000; 18: 2193-200.
70. Samowitz WS, Curtin K, Lin HH et al. The colon cancer burden of genetically defined hereditary nonpolyposis colon cancer. Gastroenterology 2001; 121: 830-8.
71. Percesepe A, Borghi F, Menigatti M et al. Molecular screening for hereditary nonpolyposis colorectal cancer: a prospective, population-based study. J Clin Oncol 2001; 19: 3944-50.
72. Cunningham JM, Kim CY, Christensen ER et al. The frequency of hereditary defective mismatch repair in a prospective series of unselected colorectal carcinomas. Am J Hum Genet 2001; 69: 780-90.
73. Pi-nol V, Castells A, Andreu M et al. Gastrointestinal Oncology Group of the Spanish Gastroenterological Association. Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. JAMA 2005; 293: 1986-94.
74. Hampel H, Frankel WL, Martin E et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med 2005; 352: 1851-60.
75. Schofield L, Watson N, Grieu F et al. Population-based detection of Lynch syndrome in young colorectal cancer patients using microsatellite instability as the initial test. Int J Cancer 2009; 124: 1097-102.
76. Wong C, Gibbs P, Johns J et al. Value of database linkage: are patients at risk of familial colorectal cancer being referred for genetic counselling and testing? Intern Med J 2008; 38: 328-33.
77. Lynch HT, Riley BD, Weissman SM et al. Hereditary nonpolyposis colorectal carcinoma (HNPCC) and HNPCC-like families: problems in diagnosis, surveillance, and management. Cancer 2004; 100: 53-64.
78. Terdiman JP. It is time to get serious about diagnosing Lynch syndrome (hereditary nonpolyposis colorectal cancer with defective DNA mismatch repair) in the general population. Gastroenterology 2005; 129: 741-4.
79. Kievit W, De Bruin JH, Adang EM et al. Current clinical selection strategies for identification of hereditary non-polyposis colorectal cancer families are inadequate: a meta-analysis. Clin Genet 2004; 65: 308-16.
80. Watson N, Grieu F, Morris M et al. Heterogeneous staining for mismatch repair proteins during population-based prescreening for hereditary nonpolyposis colorectal cancer. J Mol Diagn 2007; 9: 472-8.
81. Mangold E, Pagenstecher C, Friedl W et al. Tumours from MSH2 mutation carriers show loss of MSH2 expression but many tumours from MLH1 mutation carriers exhibit weak positive MLH1 staining. J Pathol 2005; 207: 385-95.
82. Shia J, Klimstra DS, Nafa K et al. Value of immunohistochemical detection of DNA mismatch repair proteins in predicting germline mutation in hereditary colorectal neoplasms. Am J Surg Pathol 2005; 29: 96-104.
83. Deng G, Bell I, Crawley S et al. BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer. Clin Cancer Res 2004; 10: 191-5.
84. Domingo E, Laiho P, Ollikainen M et al. BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing. J Med Genet 2004; 41: 664-8.
85. Chapelle A de la, Palomaki G, Hampel H. Identifying Lynch syndrome. Int J Cancer 2009; 125: 1492-3.
86. Jenkins MA, Dowty JG, Hopper JL, Tucker K, Southey MC. Letter in response to "Identifying Lynch syndrome" by de la Chapelle et al. Int J Cancer 2010; 126: 2757-8.